Medicus Pharma Ltd. MDCX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 43.58% | 88.86% | 134.19% | 183.83% | 101.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.80% | 67.71% | 117.29% | 187.41% | 69.29% |
| Operating Income | -90.80% | -67.71% | -117.29% | -187.41% | -69.29% |
| Income Before Tax | -89.19% | -77.22% | -326.04% | -818.76% | -70.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -89.19% | -77.22% | -326.04% | -818.76% | -70.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.11% | -77.21% | -326.04% | -818.76% | -70.00% |
| EBIT | -90.80% | -67.71% | -117.29% | -187.41% | -69.29% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 51.19% | 26.57% | -160.31% | -369.18% | 2.79% |
| Normalized Basic EPS | 49.74% | 27.60% | -158.22% | -161.12% | 5.94% |
| EPS Diluted | 51.19% | 26.57% | -160.31% | -369.18% | 2.79% |
| Normalized Diluted EPS | 49.74% | 27.60% | -158.22% | -161.12% | 5.94% |
| Average Basic Shares Outstanding | 285.40% | 141.34% | 63.66% | 95.80% | 74.85% |
| Average Diluted Shares Outstanding | 285.40% | 141.34% | 63.66% | 95.80% | 74.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |